ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY

• US 20100209403A1
• Filed: 09/02/2008
• Published: 08/19/2010
• Est. Priority Date: 09/19/2007
• Status: Active Grant

• Current Assignee: Pluri Biotech Limited
• Original Assignee: Pluristem Ltd. (Pluri Inc.)
• Inventors: Drori-Carmi, Nirit, Meiron, Moran, Aberman, Zami, Ofir, Rachel, Toren, Amir
• Granted Patent: US 8,529,888 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.

Claims

1. A method of treating a condition selected from the group consisting of ischemia, a condition requiring connective tissue regeneration and a condition requiring connective tissue repair in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of placental or adipose cells which are capable of adhering to polystyrene, thereby treating the condition in the subject.

7. The method of claim 1, wherein said cells are capable of suppressing immune reaction in the subject.

8. The method of claim 1, wherein at least 10% of said cells are at a proliferative phase.

9. The method of claim 1, wherein said ischemia is peripheral arterial disease (PAD).

10. The method claim 9, wherein said peripheral arterial disease (PAD) is critical limb ischemia (CLI).

11. The method of claim 1, wherein said ischemia comprises ischemia of the central nervous system (CNS).

12. The method of claim 1, wherein said ischemia is selected from the group consisting of peripheral arterial disease, ischemic vascular disease, ischemic heart disease, ischemic brain disease, ischemic renal disease and ischemic placenta.

13. The method of claim 1, wherein said cells are propagated using a three-dimensional (3D) culture.

14. The method of claim 13, wherein said three-dimensional (3D) culture comprises a 3D bioreactor.

15. The method of claim 13, wherein culturing of said cells in said 3D culture is effected under perfusion.

16. The method of claim 13, wherein culturing conditions of said three-dimensional culture comprise an adherent material selected from the group consisting of a polyester and a polypropylene.

17. The method of claim 1, wherein culturing of said cells is effected for at least 3 days.

18. The method of claim 1, wherein culturing of said cells is effected until at least 10% of said cells are proliferating.

19. The method of claim 13 wherein said cells comprise a positive marker expression selected from the group consisting of CD73, CD90, CD29 and CD105.

20. The method of claim 13 wherein said cells comprise a negative marker expression selected from the group consisting of CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34 and CD79.

22. The method of claim 1, wherein said cells comprise a stromal stem cell phenotype.

23. The method of claim 22, wherein said stromal stem cell phenotype comprises T cell suppression activity.

24. The method of claim 1, wherein said connective tissue comprises tendon, bone and/or ligament.

25. The method of claim 1, wherein said medical condition requiring connective tissue regeneration and/or repair is selected from the group consisting of bone fracture, bone cancer, burn wound, articular cartilage defect and deep wound.

27. The method of claim 15, wherein said perfusion rate is adjusted in order to maintain a constant glucose concentration in the culture medium.

28. The method of claim 27, wherein said constant glucose concentration is about 550 mg/L.

29. The method of claim 1, wherein said cells are propagated using a two-dimensional (2D) culture.

30. The method of claim 29, wherein said cells comprise a positive marker expression selected from the group consisting of CD90, CD105, CD73 and CD29.

2-4. -4. (canceled)

5. An article of manufacture comprising a packaging material which comprises a label for use in treating a condition selected from the group consisting of ischemia, a condition requiring connective tissue regeneration and a condition requiring connective tissue repair said packaging material packaging a pharmaceutically effective amount of placental or adipose cells which are capable of adhering to polystyrene.

6. (canceled)

21. (canceled)

26. (canceled)